Successful Anti-CLL1 CAR T-Cell Therapy in Secondary Acute Myeloid Leukemia
Secondary acute myeloid leukemia (sAML) is a high-risk AML evolving from heterogenous prior hematological disorders. Compared to de novo AML, sAML has even worse responses to current therapy and thus is associated with lower remission rates, inferior overall survival (OS) and higher relapse rates. M...
Main Authors: | Hui Zhang, Wen-Ting Gan, Wen-Ge Hao, Peng-Fei Wang, Zhuo-Yan Li, Lung-Ji Chang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-05-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2020.00685/full |
Similar Items
-
Landscape of genetic alterations of myeloid neoplasms in 305 Chinese cases
by: GOU Yang, et al.
Published: (2019-11-01) -
Genetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia
by: Alexandra Higgins, et al.
Published: (2020-07-01) -
Immune Phenomena in Myeloid Neoplasms: An “Egg or Chicken” Question
by: Wilma Barcellini, et al.
Published: (2021-09-01) -
Chronic Myelomonocytic Leukemia Gold Jubilee
by: Eric Solary, et al.
Published: (2021-07-01) -
<i>NPM1</i>-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity?
by: Fabio Forghieri, et al.
Published: (2020-11-01)